Arrowhead Pharmaceuticals
Patents, Design & Utilities
Last updated:
List of all Arrowhead Pharmaceuticals patents 75 in total
| Status | Patent |
|---|---|
Application | Utility: RNAi Inhibition of Alpha-ENaC Expression Filling date: 8 Sep 2025 Issue date: 28 Jul 2022 |
Grant | Utility: Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin Filling date: 8 Sep 2025 Issue date: 12 Jul 2022 |
Application | Utility: RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use Filling date: 8 Sep 2025 Issue date: 30 Jun 2022 |
Application | Utility: ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE Filling date: 8 Sep 2025 Issue date: 2 Jun 2022 |
Application | Utility: RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS Filling date: 8 Sep 2025 Issue date: 26 May 2022 |
Application | Utility: Methods For The Treatment Of APOC3-Related Diseases And Disorders Filling date: 8 Sep 2025 Issue date: 19 May 2022 |
Application | Utility: 5'-Cyclo-Phosphonate Modified Nucleotides Filling date: 8 Sep 2025 Issue date: 21 Apr 2022 |
Application | Utility: RNAi Inhibition of Alpha-ENaC Expression Filling date: 8 Sep 2025 Issue date: 14 Apr 2022 |
Application | Utility: RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use Filling date: 8 Sep 2025 Issue date: 24 Mar 2022 |
Application | Utility: RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION Filling date: 8 Sep 2025 Issue date: 17 Mar 2022 |
Application | Utility: RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) Filling date: 8 Sep 2025 Issue date: 3 Mar 2022 |
Grant | Utility: Organic compositions to treat EPAS1-related diseases Filling date: 8 Sep 2025 Issue date: 1 Mar 2022 |
Application | Utility: RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use Filling date: 8 Sep 2025 Issue date: 24 Feb 2022 |
Application | Utility: RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS Filling date: 8 Sep 2025 Issue date: 10 Feb 2022 |
Application | Utility: Targeting Ligands Filling date: 8 Sep 2025 Issue date: 3 Feb 2022 |
Application | Utility: ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF Filling date: 8 Sep 2025 Issue date: 27 Jan 2022 |
Grant | Utility: RNAi agents for inhibiting expression of alpha-ENaC and methods of use Filling date: 8 Sep 2025 Issue date: 4 Jan 2022 |
Grant | Utility: RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) Filling date: 8 Sep 2025 Issue date: 4 Jan 2022 |
Grant | Utility: RNAi inhibition of alpha-ENaC expression Filling date: 8 Sep 2025 Issue date: 28 Dec 2021 |
Application | Utility: RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION Filling date: 8 Sep 2025 Issue date: 23 Dec 2021 |
Grant | Utility: Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use Filling date: 8 Sep 2025 Issue date: 21 Dec 2021 |
Grant | Utility: Alpha-v beta-6 integrin ligands and uses thereof Filling date: 8 Sep 2025 Issue date: 23 Nov 2021 |
Grant | Utility: Targeting ligands Filling date: 8 Sep 2025 Issue date: 16 Nov 2021 |
Application | Utility: RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use Filling date: 8 Sep 2025 Issue date: 30 Sep 2021 |
Grant | Utility: Organic compositions to treat HSF1-related diseases Filling date: 8 Sep 2025 Issue date: 17 Aug 2021 |
Application | Utility: RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use Filling date: 8 Sep 2025 Issue date: 5 Aug 2021 |
Grant | Utility: 5'-cyclo-phosphonate modified nucleotides Filling date: 8 Sep 2025 Issue date: 3 Aug 2021 |
Application | Utility: RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS Filling date: 8 Sep 2025 Issue date: 29 Jul 2021 |
Grant | Utility: Organic compositions to treat APOC3-related diseases Filling date: 8 Sep 2025 Issue date: 20 Jul 2021 |
Application | Utility: Targeting Ligands For Therapeutic Compounds Filling date: 8 Sep 2025 Issue date: 24 Jun 2021 |
Application | Utility: Compositions and Methods for Inhibiting Gene Expression of Hif2alpha Filling date: 8 Sep 2025 Issue date: 17 Jun 2021 |
Grant | Utility: RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use Filling date: 8 Sep 2025 Issue date: 4 May 2021 |
Application | Utility: RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS Filling date: 8 Sep 2025 Issue date: 15 Apr 2021 |
Application | Utility: RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION Filling date: 8 Sep 2025 Issue date: 8 Apr 2021 |
Application | Utility: INTEGRIN TARGETING LIGANDS AND USES THEREOF Filling date: 8 Sep 2025 Issue date: 1 Apr 2021 |
Application | Utility: INTEGRIN TARGETING LIGANDS AND USES THEREOF Filling date: 8 Sep 2025 Issue date: 11 Mar 2021 |
Application | Utility: RNAI THERAPY FOR HEPATITIS B VIRUS INFECTION Filling date: 8 Sep 2025 Issue date: 25 Feb 2021 |
Grant | Utility: Compositions and methods for inhibiting gene expression of Hif2alpha Filling date: 8 Sep 2025 Issue date: 23 Feb 2021 |
Application | Utility: RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS Filling date: 8 Sep 2025 Issue date: 17 Dec 2020 |
Grant | Utility: Compositions and methods for inhibiting gene expression of factor XII Filling date: 8 Sep 2025 Issue date: 8 Dec 2020 |
Grant | Utility: Compositions and methods for inhibiting gene expression of hepatitis B virus Filling date: 8 Sep 2025 Issue date: 8 Dec 2020 |
Application | Utility: INTEGRIN LIGANDS AND USES THEREOF Filling date: 8 Sep 2025 Issue date: 26 Nov 2020 |
Grant | Utility: RNAi therapy for hepatitis B virus infection Filling date: 8 Sep 2025 Issue date: 20 Oct 2020 |
Application | Utility: RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use Filling date: 8 Sep 2025 Issue date: 24 Sep 2020 |
Application | Utility: RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) Filling date: 8 Sep 2025 Issue date: 24 Sep 2020 |
Grant | Utility: RNAi agents for Hepatitis B virus infection Filling date: 8 Sep 2025 Issue date: 22 Sep 2020 |
Application | Utility: RNAi Agents And Compositions for Inhibiting Expression of Asiaglycoprotein Receptor 1 Filling date: 8 Sep 2025 Issue date: 10 Sep 2020 |
Application | Utility: RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS Filling date: 8 Sep 2025 Issue date: 3 Sep 2020 |
Application | Utility: Compositions and Methods for Inhibiting Expression of RRM2 Genes Filling date: 8 Sep 2025 Issue date: 3 Sep 2020 |
Application | Utility: COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA Filling date: 8 Sep 2025 Issue date: 20 Aug 2020 |
Showing 1 to 50 of 75 patents.